Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2014, Article ID 638747, 13 pages
http://dx.doi.org/10.1155/2014/638747
Research Article

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

1Biomarkers and Personalized Medicine Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
2Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
3Biomarkers and Personalized Medicine Core Function Unit, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA

Received 12 June 2014; Accepted 26 August 2014; Published 10 September 2014

Academic Editor: Giovanni Tallini

Copyright © 2014 Osamu Tohyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [108 citations]

The following is the list of published articles that have cited the current article.

  • Kiyoshi Okamoto, Megumi Ikemori-Kawada, Anja Jestel, Konstanze von König, Yasuhiro Funahashi, Tomohiro Matsushima, Akihiko Tsuruoka, Atsushi Inoue, and Junji Matsui, “Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization,” ACS Medicinal Chemistry Letters, pp. 141120111050009, 2014. View at Publisher · View at Google Scholar
  • Steven P. Weitzman, and Maria E. Cabanillas, “The treatment landscape in thyroid cancer: A focus on cabozantinib,” Cancer Management and Research, vol. 7, pp. 265–278, 2015. View at Publisher · View at Google Scholar
  • Ammad Ahmad Farooqi, and Zahid H. Siddik, “Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape,” Cell Biochemistry and Function, 2015. View at Publisher · View at Google Scholar
  • Teresa Helsten, Maria Schwaederle, and Razelle Kurzrock, “Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications,” Cancer and Metastasis Reviews, 2015. View at Publisher · View at Google Scholar
  • Alessandro Antonelli, Poupak Fallahi, Salvatore Ulisse, Silvia Martina Ferrari, Valeria Mazzi, Andrea Di Domenicantonio, and Paolo Miccoli, “Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer,” International Journal of Endocrine Oncology, pp. 1–8, 2015. View at Publisher · View at Google Scholar
  • Lesley J. Scott, “Lenvatinib: First Global Approval,” Drugs, vol. 75, no. 5, pp. 553–560, 2015. View at Publisher · View at Google Scholar
  • Maria E. Cabanillas, and Mouhammed Amir Habra, “Lenvatinib: Role in Thyroid Cancer and Other Solid Tumors,” Cancer Treatment Reviews, 2015. View at Publisher · View at Google Scholar
  • Kay T. Yeung, and Ezra E. W. Cohen, “Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma,” Clinical Cancer Research, vol. 21, no. 24, pp. 5420–5426, 2015. View at Publisher · View at Google Scholar
  • M. Hegazi, A. Azadi, D. Jain, R. Redman, and C. A. Perez, “Pharmacological And Clinical Profile Of Lenvatinib (E-7080) In The Treatment Of Advanced, Radioiodine-Refractory, Differentiated Thyroid Cancer,” Drugs Of Today, vol. 51, no. 12, pp. 689–694, 2015. View at Publisher · View at Google Scholar
  • Shinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Kazunori Honda, Yosuke Tamura, Hiroshi Wakui, Tatsuya Sasaki, Wataru Yusa, Katsuki Fujino, and Tomohide Tamura, “A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors,” Cancer Chemotherapy and Pharmacology, 2015. View at Publisher · View at Google Scholar
  • Akihiko Tsuruoka, Junji Matsui, Takuya Suzuki, Noriyuki Koyama, Tatsuo Watanabe, and Yasuhiro Funahashi, “Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment,” Folia Pharmacologica Japonica, vol. 146, no. 5, pp. 283–290, 2015. View at Publisher · View at Google Scholar
  • Masaru Katoh, “FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review),” International Journal of Molecular Medicine, vol. 38, no. 1, pp. 3–15, 2016. View at Publisher · View at Google Scholar
  • Xiaotong Wang, Yan Mou, Zhen Yue, Haiying Zhang, Xuejin Su, Yang Wang, Ronggui Li, and Xin Sun, “Arsenite suppresses angiogenesis of vascular endothelial cells mediated by Platelet Derived Growth Factor Receptor-beta,” Environmental Toxicology and Pharmacology, 2016. View at Publisher · View at Google Scholar
  • Kazufumi Obata, Iwao Sugitani, Aya Ebina, Yoshiya Sugiura, Kazuhisa Toda, Shunji Takahashi, and Kazuyoshi Kawabata, “Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer,” International Cancer Conference Journal, 2016. View at Publisher · View at Google Scholar
  • Jolanta Krajewska, Aleksandra Kukulska, and Barbara Jarzab, “Efficacy of lenvatinib in treating thyroid cancer,” Expert Opinion on Pharmacotherapy, pp. 1–9, 2016. View at Publisher · View at Google Scholar
  • Hilary Glen, “Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma,” Future Oncology, 2016. View at Publisher · View at Google Scholar
  • Anubha Gupta, Barbara Jarzab, Jaume Capdevila, Robert Shumaker, and Ziad Hussein, “Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer,” British Journal of Clinical Pharmacology, vol. 81, no. 6, pp. 1124–1133, 2016. View at Publisher · View at Google Scholar
  • Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, and Hiromitsu Kumada, “Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma,” Clinical Cancer Research, vol. 22, no. 6, pp. 1385–1394, 2016. View at Publisher · View at Google Scholar
  • Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, Robert S. Jansen, Hilde Rosing, Hitoshi Mizuo, Shinki Kawaguchi, David Critchley, Robert Shumaker, Jan H. M. Schellens, and Jos H. Beijnen, “Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison,” Investigational New Drugs, 2016. View at Publisher · View at Google Scholar
  • James E. Frampton, “Lenvatinib: A Review in Refractory Thyroid Cancer,” Targeted Oncology, vol. 11, no. 1, pp. 115–122, 2016. View at Publisher · View at Google Scholar
  • Tadas Rimkus, Richard Carpenter, Shadi Qasem, Michael Chan, and Hui-Wen Lo, “Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors,” Cancers, vol. 8, no. 2, pp. 22, 2016. View at Publisher · View at Google Scholar
  • Christelle de la Fouchardiere, “Place du lenvatinib dans les cancers thyroïdiens réfractaires à l’iode,” Bulletin du Cancer, 2016. View at Publisher · View at Google Scholar
  • Jena D French, Keith Bible, Christine Spitzweg, Bryan R Haugen, and Mabel Ryder, “Leveraging the immune system to treat advanced thyroid cancers,” The Lancet Diabetes & Endocrinology, 2016. View at Publisher · View at Google Scholar
  • Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, and Hiromitsu Kumada, “Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma,” Journal of Gastroenterology, 2016. View at Publisher · View at Google Scholar
  • Rossella Elisei, Laura Agate, Sara Mazzarri, Valeria Bottici, Federica Guidoccio, Eleonora Molinaro, Giuseppe Boni, Marco Ferdeghini, and Giuliano Mariani, “Radionuclide Therapy of Thyroid Tumors,” Nuclear Oncology, pp. 1–47, 2016. View at Publisher · View at Google Scholar
  • Salvatore Mazzeo, Eleonora Molinaro, Laura Valerio, Valentina Battaglia, Loredana Lorusso, Rossella Elisei, Letizia Pieruzzi, Agnese Biagini, Elena Sabini, Carlotta Giani, Paolo Passannanti, and Benedetta Pontillo-Contillo, “Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer,” OncoTargets and Therapy, vol. 9, pp. 6467–6477, 2016. View at Publisher · View at Google Scholar
  • Giovanni Vitale, Germano Gaudenzi, Luisa Circelli, Marco F Manzoni, Andrea Bassi, Niccolò Fioritti, Antongiulio Faggiano, and Annamaria Colao, “Animal models of medullary thyroid cancer: state of the art and view to the future,” Endocrine-Related Cancer, vol. 24, no. 1, pp. R1–R12, 2016. View at Publisher · View at Google Scholar
  • Martin Schlumberger, Renato G. Martins, Lisa F. Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman, Barbara Jarzab, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith McCaffrey, Kate Newbold, and Roger Allison, “A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer,” Clinical Cancer Research, vol. 22, no. 1, pp. 44–53, 2016. View at Publisher · View at Google Scholar
  • Ricardo Costa, Benedito A. Carneiro, Sunandana Chandra, Sachin G. Pai, Young Kwang Chae, Jason B. Kaplan, Hannah B. Garrett, Mark Agulnik, Peter A. Kopp, and Francis J. Giles, “Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives,” Drug Design Development And Therapy, vol. 10, pp. 873–884, 2016. View at Publisher · View at Google Scholar
  • Jen-Wei Liu, Chiehfeng Chen, El-Wui Loh, Chun-Cheng Chu, Mu-Yi Wang, Hsin-Ju Ouyang, Ya-Ting Chang, Wei-Zhan Zhuang, Ching-Wen Chou, Der-Jr Huang, Chia-Hwa Lee, Yun Yen, and Ka-Wai Tam, “Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials,” Current Medical Research and Opinion, pp. 1–9, 2017. View at Publisher · View at Google Scholar
  • Masatoshi Kudo, “Lenvatinib in Advanced Hepatocellular Carcinoma,” Liver Cancer, pp. 253–263, 2017. View at Publisher · View at Google Scholar
  • Marcia S. Brose, Francis P. Worden, Kate L. Newbold, Matthew Guo, and Arti Hurria, “Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial,” Journal of Clinical Oncology, vol. 35, no. 23, pp. 2692–2699, 2017. View at Publisher · View at Google Scholar
  • Qin Xie, Hui Chen, Jing Ai, Ying-lei Gao, Mei-yu Geng, Jian Ding, and Yi Chen, “Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer,” Acta Pharmacologica Sinica, 2017. View at Publisher · View at Google Scholar
  • Eleonora Molinaro, Cristina Romei, Agnese Biagini, Elena Sabini, Laura Agate, Salvatore Mazzeo, Gabriele Materazzi, Stefano Sellari-Franceschini, Alessandro Ribechini, Liborio Torregrossa, Fulvio Basolo, Paolo Vitti, and Rossella Elisei, “Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies,” Nature Reviews Endocrinology, 2017. View at Publisher · View at Google Scholar
  • Poupak Fallahi, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Salvatore Ulisse, Enke Baldini, Mario Miccoli, Gabriele Materazzi, Alessandro Antonelli, and Silvia Martina Ferrari, “Novel treatment options for anaplastic thyroid cancer,” Expert Review of Endocrinology & Metabolism, pp. 1–10, 2017. View at Publisher · View at Google Scholar
  • Masahiro Matsuki, Yusuke Adachi, Yoichi Ozawa, Takayuki Kimura, Taisuke Hoshi, Kiyoshi Okamoto, Osamu Tohyama, Kaoru Mitsuhashi, Atsumi Yamaguchi, Junji Matsui, and Yasuhiro Funahashi, “Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus,” Cancer Science, 2017. View at Publisher · View at Google Scholar
  • Makoto Tahara, Martin Schlumberger, Rossella Elisei, Mouhammed Amir Habra, Naomi Kiyota, Ralf Paschke, Corina E. Dutcus, Taro Hihara, Shannon McGrath, Mark Matijevic, Tadashi Kadowaki, Yasuhiro Funahashi, and Steven I. Sherman, “Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid,” European Journal of Cancer, vol. 75, pp. 213–221, 2017. View at Publisher · View at Google Scholar
  • Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina E. Dutcus, and Shunji Takahashi, “Lenvatinib for Anaplastic Thyroid Cancer,” Frontiers in Oncology, vol. 7, 2017. View at Publisher · View at Google Scholar
  • Ziad Hussein, Hitoshi Mizuo, Seiichi Hayato, Masayuki Namiki, and Robert Shumaker, “Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor,” European Journal of Drug Metabolism and Pharmacokinetics, 2017. View at Publisher · View at Google Scholar
  • Matti L. Gild, Duncan J. Topliss, Diana Learoyd, Francis Parnis, Jeanne Tie, Brett Hughes, John P. Walsh, Donald S.A. McLeod, Roderick J. Clifton-Bligh, and Bruce G. Robinson, “Clinical guidance for radioiodine refractory differentiated thyroid cancer,” Clinical Endocrinology, 2017. View at Publisher · View at Google Scholar
  • Shunji Takahashi, Naomi Kiyota, and Makoto Tahara, “Optimal use of lenvatinib in the treatment of advanced thyroid cancer,” Cancers of the Head & Neck, vol. 2, no. 1, 2017. View at Publisher · View at Google Scholar
  • Emi Date, Kunio Okamoto, Souichi Fumita, and Hiroyasu Kaneda, “Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer,” Investigational New Drugs, 2017. View at Publisher · View at Google Scholar
  • Rossella Elisei, Laura Agate, Sara Mazzarri, Valeria Bottici, Federica Guidoccio, Eleonora Molinaro, Giuseppe Boni, Marco Ferdeghini, and Giuliano Mariani, “Radionuclide Therapy of Thyroid Tumors,” Nuclear Oncology, pp. 1197–1241, 2017. View at Publisher · View at Google Scholar
  • Chie Masaki, Kiminori Sugino, Naoko Saito, Yoshiyuki Saito, Tomoaki Tanaka, Yuna Ogimi, Tetsuyo Maeda, Tadatoshi Osaku, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Hiroshi Takami, and Koichi Ito, “Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma,” Endocrine Journal, vol. 64, no. 8, pp. 819–826, 2017. View at Publisher · View at Google Scholar
  • Uwe Rix, Rebecca E. Schweppe, Katie M. Mishall, Thomas C. Beadnell, Brent M. Kuenzi, Dorothy M. Klimczak, and Giulio Superti-Furga, “Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer,” Oncotarget, vol. 8, no. 61, pp. 103014–103031, 2017. View at Publisher · View at Google Scholar
  • Jun-Ichi Ohkubo, Azusa Takahashi, Shoji Ikezaki, Fumiko Takenaga, Yufu Ohkubo, and Hideaki Suzuki, “Anaplastic Thyroid Carcinoma Treated with Lenvatinib,” The Kurume Medical Journal, 2017. View at Publisher · View at Google Scholar
  • Masafumi Ikeda, Masahiro Kobayashi, Makoto Tahara, and Shuichi Kaneko, “Optimal management of patients with hepatocellular carcinoma treated with lenvatinib,” Expert Opinion on Drug Safety, pp. 1–11, 2018. View at Publisher · View at Google Scholar
  • Seiichi Hayato, Robert Shumaker, Jim Ferry, Terri Binder, Corina E. Dutcus, and Ziad Hussein, “Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer,” Cancer Chemotherapy and Pharmacology, 2018. View at Publisher · View at Google Scholar
  • Stefanie Zschäbitz, and Carsten Grüllich, “Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET,” Small Molecules in Oncology, vol. 211, pp. 187–198, 2018. View at Publisher · View at Google Scholar
  • Nobuaki Matsubara, Yoichi Naito, Kenji Nakano, Yutaka Fujiwara, Hiroki Ikezawa, Wataru Yusa, Masayuki Namiki, Takashi Okude, and Shunji Takahashi, “Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study,” International Journal of Urology, 2018. View at Publisher · View at Google Scholar
  • Hilary Glen, Mark A. Baxter, and Thomas R. Evans, “Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma,” Future Oncology, vol. 14, no. 20, pp. 2021–2029, 2018. View at Publisher · View at Google Scholar
  • M. S. Brose, F. P. Worden, K. L. Newbold, M. Guo, and A. Hurria, “Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial,” Head and neck tumors (HNT), vol. 8, no. 2, pp. 39–52, 2018. View at Publisher · View at Google Scholar
  • Brian W. Kim, “Some Advanced Thyroid Cancer Patients Have a Prolonged Response to Lenvatinib,” Clinical Thyroidology, vol. 30, no. 7, pp. 305–308, 2018. View at Publisher · View at Google Scholar
  • Masayuki Tori, and Toshirou Shimo, “Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report,” BMC Cancer, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar
  • Yuji Eso, and Hiroyuki Marusawa, “Novel approaches for molecular targeted therapy against hepatocellular carcinoma,” Hepatology Research, 2018. View at Publisher · View at Google Scholar
  • Hana Študentová, Denisa Vitásková, and Bohuslav Melichar, “Lenvatinib for the treatment of kidney cancer,” Expert Review of Anticancer Therapy, pp. 1–8, 2018. View at Publisher · View at Google Scholar
  • Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori-Kawada, Yukinori Minoshima, Yasuhiro Funahashi, and Junji Matsui, “Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models,” Cancer Medicine, 2018. View at Publisher · View at Google Scholar
  • Andrew G Gianoukakis, Corina E Dutcus, Nicolas Batty, Matthew Guo, and Mahadi Baig, “Prolonged duration of response in lenvatinib responders with thyroid cancer,” Endocrine-Related Cancer, vol. 25, no. 6, pp. 699–704, 2018. View at Publisher · View at Google Scholar
  • Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem, Jean Frederic Blanc, Arndt Vogel, Dmitry Komov, T R Jeffry Evans, Carlos Lopez, Corina Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, and Ann-Lii Cheng, “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial,” The Lancet, vol. 391, no. 10126, pp. 1163–1173, 2018. View at Publisher · View at Google Scholar
  • Delia De Lisi, Ugo De Giorgi, Cristian Lolli, Giuseppe Schepisi, Vincenza Conteduca, Cecilia Menna, Giuseppe Tonini, Daniele Santini, and Alberto Farolfi, “Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?,” Expert Opinion on Drug Metabolism & Toxicology, pp. 1–7, 2018. View at Publisher · View at Google Scholar
  • Masatoshi Kudo, “Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma,” Liver Cancer, vol. 7, no. 1, pp. 1–19, 2018. View at Publisher · View at Google Scholar
  • Yong Sang Lee, Seok-Mo Kim, Bup-Woo Kim, Ho Jin Chang, Soo Young Kim, Cheong Soo Park, Ki Cheong Park, and Hang-Seok Chang, “Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells,” Neoplasia, vol. 20, no. 2, pp. 197–206, 2018. View at Publisher · View at Google Scholar
  • Maria E. Cabanillas, and Shunji Takahashi, “Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer,” Seminars in Oncology, 2018. View at Publisher · View at Google Scholar
  • Silvia Martina Ferrari, Concettina La Motta, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Luca Quattrini, Sabrina Rosaria Paparo, Simona Piaggi, Armando Patrizio, Salvatore Ulisse, Enke Baldini, Gabriele Materazzi, Poupak Fallahi, and Alessandro Antonelli, “Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration,” Frontiers in Endocrinology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Haruhiko Yamazaki, Hirotaka Takasaki, Hirotaka Nakayama, Katsuhiko Masudo, Hiroyuki Iwasaki, Nobuyasu Suganuma, and Soji Toda, “Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study,” Oncology Letters, vol. 16, no. 6, pp. 7271–7277, 2018. View at Publisher · View at Google Scholar
  • Renzhi Yu, Xiuli Zhu, Zhe Sun, Aiying Jiang, Huixin Yao, and Minghuan Wang, “Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer,” Oncology Letters, vol. 16, no. 5, pp. 6573–6581, 2018. View at Publisher · View at Google Scholar
  • A. G. Gianoukakis, C. E. Dutcus, N. Batty, M. Guo, and M. Baig, “Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation),” Head and neck tumors (HNT), vol. 8, no. 3, pp. 53–60, 2018. View at Publisher · View at Google Scholar
  • Takayuki Kimura, Yu Kato, Yoichi Ozawa, Kotaro Kodama, Junichi Ito, Kenji Ichikawa, Kazuhiko Yamada, Yusaku Hori, Kimiyo Tabata, Kazuma Takase, Junji Matsui, Yasuhiro Funahashi, and Kenichi Nomoto, “Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model,” Cancer Science, 2018. View at Publisher · View at Google Scholar
  • Priya Mahajan, Jonathan Dawrant, Albert Kheradpour, Norma M. Quintanilla, Monica E. Lopez, Robert C. Orth, Ioanna Athanassaki, and Rajkumar Venkatramani, “Response to Lenvatinib in Children with Papillary Thyroid Carcinoma,” Thyroid, 2018. View at Publisher · View at Google Scholar
  • Soo Young Kim, Seok-Mo Kim, Ho-Jin Chang, Bup-Woo Kim, Yong Sang Lee, Cheong Soo Park, Ki Cheong Park, and Hang-Seok Chang, “SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer,” BMC Cancer, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar
  • Masaru Katoh, “Fibroblast growth factor receptors as treatment targets in clinical oncology,” Nature Reviews Clinical Oncology, 2018. View at Publisher · View at Google Scholar
  • Masatoshi Kudo, “Systemic Therapy for Hepatocellular Carcinoma: Latest Advances,” Cancers, vol. 10, no. 11, pp. 412, 2018. View at Publisher · View at Google Scholar
  • Guoyu Wang, Juhua Zhuang, Jing Ni, Ying Ye, Saifei He, and Wei Xia, “Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress,” Experimental and Therapeutic Medicine, vol. 16, no. 4, pp. 3325–3332, 2018. View at Publisher · View at Google Scholar
  • Hongxia Sun, Xiaotong Wang, Yunyun Li, Yan Mou, Zhen Yue, Haiying Zhang, and Ronggui Li, “Ethanol extract from brucea javanica seed inhibits angiogenesis mediated by platelet derived growth factor receptor-beta,” International Journal of Medical Sciences, vol. 15, no. 13, pp. 1517–1521, 2018. View at Publisher · View at Google Scholar
  • Silvia Martina Ferrari, Enke Baldini, Gabriele Materazzi, Salvatore Ulisse, Poupak Fallahi, Guido Bocci, Ilaria Ruffilli, Paola Orlandi, Sabrina Rosaria Paparo, Simona Piaggi, Concettina La Motta, Teresa Di Desidero, Francesca Ragusa, Paolo Miccoli, Alessandro Antonelli, Giusy Elia, and Armando Patrizio, “Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo,” Oncology Reports, vol. 39, no. 5, pp. 2225–2234, 2018. View at Publisher · View at Google Scholar
  • Marco Centanni, Magdalini Alexopoulou, Mario Miccoli, Poupak Fallaih, Silvia M. Ferrari, Ilaria Ruffilli, Camilla Virili, Gabriele Materazzi, and Alessandro Antonelli, “Lenvatinib in the therapy of aggressive thyroid cancer: State of the art and new perspectives with patents recently applied,” Recent Patents on Anti-Cancer Drug Discovery, vol. 13, no. 2, pp. 201–208, 2018. View at Publisher · View at Google Scholar
  • Eyun Song, and Won Gu Kim, “Management of Hypertension and Proteinuria after Treatment with Lenvatinib for Radioiodine Refractory Papillary Thyroid Carcinoma: a Case Report,” International Journal of Thyroidology, vol. 11, no. 2, pp. 78, 2018. View at Publisher · View at Google Scholar
  • Yu-Yang Lin, Ann-Lii Cheng, Ching-Ting Tan, Chia-Wei Chen, Da-Liang Ou, and Chiun Hsu, “Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy,” Seminars in Liver Disease, vol. 38, no. 4, pp. 379–388, 2018. View at Publisher · View at Google Scholar
  • Toyoaki Hida, Vamsidhar Velcheti, Karen L. Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E. Dutcus, Min Ren, and Tomohide Tamura, “A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma,” Lung Cancer, 2019. View at Publisher · View at Google Scholar
  • Hironobu Yagishita, Shinichiro Minami, Yumiko Akamine, Shotaro Kato, Katsunori Iijima, and Masatomo Miura, “ Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9 * 1/*3 and VKORC1 ‐1639G/A genotype ,” Journal of Clinical Pharmacy and Therapeutics, 2019. View at Publisher · View at Google Scholar
  • Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario D’Andrea, and Giuseppe Toffoli, “Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 25, no. 29, pp. 3870–3896, 2019. View at Publisher · View at Google Scholar
  • Agnese Latorre, Agnese Maria Fioretti, Francesco Giotta, and Vito Lorusso, “Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report,” Future Oncology, 2019. View at Publisher · View at Google Scholar
  • Elizabeth R. McGonagle, and Carmelo Nucera, “Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy,” Frontiers in Endocrinology, vol. 10, 2019. View at Publisher · View at Google Scholar
  • Akihiko Tsuruoka, Yasuhiro Funahashi, Junji Matsui, and Tomohiro MatsushimaSuccessful Drug Discovery, pp. 155–168, 2019. View at Publisher · View at Google Scholar
  • Takatoshi Nawa, Kazuhiro Katayama, Ryosuke Kiyota, Toshihiro Imai, Yutaro Abe, Noriko Hasegawa, Ryoji Takada, Nobuyasu Fukutake, Kenji Ikezawa, Mitsuru Sakakibara, Masashi Fujita, and Kazuyoshi Ohkawa, “Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma,” Clinical Journal of Gastroenterology, 2019. View at Publisher · View at Google Scholar
  • Christelle de la Fouchardiere, Abir Alghuzlan, Stéphane Bardet, Isabelle Borget, Françoise Borson Chazot, Christine Do Cao, Yann Godbert, Laurence Leenhardt, Slimane Zerdoud, and Sophie Leboulleux, “The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review,” Bulletin du Cancer, 2019. View at Publisher · View at Google Scholar
  • Shuzhen Chen, Qiqi Cao, Wen Wen, and Hongyang Wang, “Targeted Therapy for Hepatocellular Carcinoma: Challenges and Opportunities,” Cancer Letters, 2019. View at Publisher · View at Google Scholar
  • Kehua Zhou, and Christos Fountzilas, “Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma,” Cancers, vol. 11, no. 6, pp. 861, 2019. View at Publisher · View at Google Scholar
  • Hidekatsu Kuorda, Tamami Abe, Yudai Fujiwara, Takuya Okamoto, Miki Yonezawa, Hiroki Sato, Kei Endo, Takayoshi Oikawa, Kei Sawara, and Yasuhiro Takikawa, “Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 25, no. 19, pp. 2365–2372, 2019. View at Publisher · View at Google Scholar
  • M. Tahara, M. S. Brose, L. J. Wirth, T. Suzuki, H. Miyagishi, K. Fujino, C. E. Dutcus, and A. Gianoukakis, “Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы,” Head and neck tumors (HNT), vol. 9, no. 1, pp. 38–50, 2019. View at Publisher · View at Google Scholar
  • Zaina T. Al-Salama, Yahiya Y. Syed, and Lesley J. Scott, “Lenvatinib: A Review in Hepatocellular Carcinoma,” Drugs, 2019. View at Publisher · View at Google Scholar
  • Tomoko Ozeki, Mitsuji Nagahama, Kazuma Fujita, Akifumi Suzuki, Kiminori Sugino, Koichi Ito, and Masatomo Miura, “Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer,” Scientific Reports, vol. 9, no. 1, 2019. View at Publisher · View at Google Scholar
  • Kohei Kotani, Masaru Enomoto, Masako Okada, Kanako Yoshida, Hiroyuki Motoyama, Hideki Fujii, Atsushi Hagihara, Sawako Uchida-Kobayashi, Hiroyasu Morikawa, Yoshiki Murakami, Akihiro Tamori, and Norifumi Kawada, “Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma,” Clinical Journal of Gastroenterology, 2019. View at Publisher · View at Google Scholar
  • Vatche Tchekmedyian, Eric J. Sherman, Lara Dunn, Crystal Tran, Shrujal Baxi, Nora Katabi, Cristina R. Antonescu, Irina Ostrovnaya, Sofia S. Haque, David G. Pfister, and Alan L. Ho, “Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma,” Journal of Clinical Oncology, pp. JCO.18.01859, 2019. View at Publisher · View at Google Scholar
  • Yusuke Adachi, Masahiro Matsuki, Hideki Watanabe, Kazuma Takase, Kotaro Kodama, Junji Matsui, Yasuhiro Funahashi, and Kenichi Nomoto, “Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma,” Cancer Investigation, pp. 1–14, 2019. View at Publisher · View at Google Scholar
  • Mitsuji Nagahama, Tomoko Ozeki, Akifumi Suzuki, Kiminori Sugino, Takenori Niioka, Koichi Ito, and Masatomo Miura, “Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer,” Medical Oncology, vol. 36, no. 5, 2019. View at Publisher · View at Google Scholar
  • Marilena Celano, Valentina Maggisano, Saverio Massimo Lepore, Marialuisa Sponziello, Valeria Pecce, Antonella Verrienti, Cosimo Durante, Marianna Maranghi, Piernatale Lucia, Stefania Bulotta, Giuseppe Damante, and Diego Russo, “Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells,” International Journal of Endocrinology, vol. 2019, pp. 1–6, 2019. View at Publisher · View at Google Scholar
  • Yu Kato, Kimiyo Tabata, Takayuki Kimura, Ayako Yachie-Kinoshita, Yoichi Ozawa, Kazuhiko Yamada, Junichi Ito, Sho Tachino, Yusaku Hori, Masahiro Matsuki, Yukiko Matsuoka, Samik Ghosh, Hiroaki Kitano, Kenichi Nomoto, Junji Matsui, and Yasuhiro Funahashi, “Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway,” Plos One, vol. 14, no. 2, pp. e0212513, 2019. View at Publisher · View at Google Scholar
  • Takahiro Maeda, Hiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, Kengo Kanayama, Susumu Maruta, Yuko Kusakabe, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Ryo Nakagawa, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, and Naoya Kato, “Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma,” BMC Cancer, vol. 19, no. 1, 2019. View at Publisher · View at Google Scholar
  • Hazem A. Mahdy, Mohammed K. Ibrahim, Ahmed M. Metwaly, Amany Belal, Ahmed B.M. Mehany, Abdou El-Sharkawy, Mostafa A. Elhendawy, Mohamed M. Radwan, Mahmoud A. Elsohly, and Ibrahim H. Eissa, “Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers,” Bioorganic Chemistry, pp. 103422, 2019. View at Publisher · View at Google Scholar
  • Makoto Tahara, Marcia S. Brose, Lori J. Wirth, Takuya Suzuki, Hideaki Miyagishi, Katsuki Fujino, Corina E. Dutcus, and Andrew Gianoukakis, “Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer,” European Journal of Cancer, vol. 106, pp. 61–68, 2019. View at Publisher · View at Google Scholar
  • Maiko Namba, Tomokazu Kawaoka, Hiroshi Aikata, Kenichiro Kodama, Shinsuke Uchikawa, Kazuki Ohya, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yasutaka Baba, Kazuo Awai, and Kazuaki Chayama, “Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt,” Clinical Journal of Gastroenterology, 2019. View at Publisher · View at Google Scholar
  • Viswanath Gunda, Benjamin Gigliotti, Tameem Ashry, Dorothy Ndishabandi, Michael McCarthy, Zhiheng Zhou, Salma Amin, Kyu Eun Lee, Tabea Stork, Lori Wirth, Gordon J. Freeman, Alessandro Alessandrini, and Sareh Parangi, “Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer,” International Journal of Cancer, 2019. View at Publisher · View at Google Scholar
  • Silvia Martina Ferrari, Poupak Fallahi, Concettina La Motta, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Armando Patrizio, Enke Baldini, Salvatore Ulisse, and Alessandro Antonelli, “Recent advances in precision medicine for the treatment of anaplastic thyroid cancer,” Expert Review of Precision Medicine and Drug Development, pp. 1–13, 2019. View at Publisher · View at Google Scholar
  • Haruhiko Takeda, Norihiro Nishijima, Akihiro Nasu, Hideyuki Komekado, Ryuichi Kita, Toru Kimura, Masatoshi Kudo, and Yukio Osaki, “Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion,” Hepatology Research, 2019. View at Publisher · View at Google Scholar
  • Masahiro Kobayashi, “Lenvatinib: New molecular targeted therapy of hepatocellular carcinoma-the progress and future perspective,” Journal of Japanese Society of Gastroenterology, vol. 116, no. 1, pp. 36–44, 2019. View at Publisher · View at Google Scholar
  • Yohei Koizumi, Masashi Hirooka, Atsushi Hiraoka, Hironori Ochi, Takaaki Tanaka, Atsushi Yukimoto, Yuusuke Imai, Takao Watanabe, Osamu Yoshida, Teruki Miyake, Bunzo Matsuura, Kojiro Michitaka, Kouji Joko, Masanori Abe, and Yoichi Hiasa, “Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma,” Endocrine Journal, vol. 66, no. 9, pp. 787–792, 2019. View at Publisher · View at Google Scholar
  • Masashi Hirooka, Hironori Ochi, Atsushi Hiraoka, Yohei Koizumi, Bunzo Matsuura, Kouji Joko, Kojiro Michitaka, Masanori Abe, and Yoichi Hiasa, “Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma,” Internal Medicine, 2019. View at Publisher · View at Google Scholar